Fig. 5.

ID8-Defb29/Vegf-a-Luc ovarian tumor challenge and re-challenge in vaccinated mice. (a) Vaccination and tumor challenge and re-challenge schedule for C57BL/6 mice. All vaccines were i.p. administered using a prime-boost regimen with injections spaced one week apart. 5 × 10⁶ ID8-Defb29/Vegf-a-Luc cancer cells were i.p. administered 7 days past the second injection. Any surviving mice were re-challenged at day 103 with näıve mice. (b) Survival rates of vaccinated mice. All mice surviving over 100 days post-initial tumor challenge were re-challenged with 5 × 10⁶ ID8-Defb29/Vegf-a-Luc cancer cells as indicated by the grey dashed line. (c) Survival rate of the rechallenged mice. (d) Circumferences of the mice were monitored as a sign of tumor progression. (e) Individual circumferences of age-matched, naïve mice following ID8-Defb29/Vegf-a-Luc injection for the re-challenge experiment. Figures were generated using Biorender and GraphPad Prism 8.